P170002/S059: RHA 2, RHA 3, RHA 4
FDA’s recorded scope: Approval for an alternative qualified laboratory for Biological Indicator release testing as part of receiving inspection
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 10 FDA records to the applicant name Teoxane S.A.. 7 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 18, 2025 to Aug 31, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LMH appears in 10 of the 10 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P170002, with 10 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: Les Charmilles Rue De Lyon, 105, Geneva, 1203. Recorded on P170002/S059, decision dated Aug 31, 2026.
FDA’s recorded scope: Approval for an alternative qualified laboratory for Biological Indicator release testing as part of receiving inspection
FDA’s recorded scope: Approval for the replacement of glass crystallizers with Stainless Steel 316L crystallizers
FDA’s recorded scope: approval for updating the labeling of RHA3 Mepi to a new commercial name, RHA Kiss Volume, that includes a smaller gauge (30G) needle in its packaging, color change to the syringe finger grip and plunger rod, and updated labeling including use of 27G or 30G needle when injecting for both approved indications, in the lips and nasolabial folds.
FDA’s recorded scope: Approval for the final labeling of RHA Redensity Mepi. This follows the completion of the post-approval study to investigate whether RHA Redensity Mepi (with mepivacaine) is non-inferior to RHA Redensity (with lidocaine) for injection site pain felt during injection in FST V/VI subjects.
FDA’s recorded scope: Approval for RHA Redensity Eye Lido and RHA Redensity Eye for expanding the indications to include injection into the sub-dermis and supraperiosteum for the correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults aged 22 years or older.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RHA 2, RHA 3, RHA 4P170002/S059 | Teoxane S.A. | PMA supplement | Aug 31, 2026 | FDA |
RHA 2, RHA 3, RHA 4P170002/S058 | Teoxane S.A. | PMA supplement | Aug 28, 2026 | FDA |
RHA Kiss VolumeP170002/S055 | Teoxane S.A. | PMA supplement | Jul 27, 2026 | FDA |
RHA Redensity, RHA Redensity MepiP170002/S052 | Teoxane S.A. | PMA supplement | Jul 2, 2026 | FDA |
RHA Redensity Eye Lido; RHA Redensity EyeP170002/S050 | Teoxane S.A. | PMA supplement | May 12, 2026 | FDA |
RHA 2, RHA 3, RHA 4P170002/S041 | Teoxane S.A. | PMA supplement | Apr 7, 2026 | FDA |
| Teoxane S.A. | PMA supplement | Apr 1, 2026 | FDA | |
| Teoxane S.A. | PMA supplement | Mar 31, 2026 | FDA | |
RHA Redensity dermal fillerP170002/S051 | Teoxane S.A. | PMA supplement | Jan 14, 2026 | FDA |
RHA Dynamic Volume, RHA4P170002/S048 | Teoxane S.A. | PMA supplement | Sep 18, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 20, 2026.